Jefferies Downgrades Fusion Pharmaceuticals (FUSN) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Equities close higher as softer jobs data quiets rate-hike expectations
- U.S. economy adds fewer jobs than expected as unemployment rate ticks higher
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- Citi says rate volatility without Fed repricing is concerning
- U.S. credit-reporting stocks fall as FHFA weighs two-bureau mortgage rule
- Equities close higher as softer jobs data quiets rate-hike expectations
- Cantor Fitzgerald on Rivian (RIVN): 'pre-announced that it delivered 19,248 vehicles in 3Q26, above our estimate'
- Nvidia returns as Morgan Stanley’s Top Pick on attractive valuation
- DISH DBS emerges from bankruptcy, cuts debt by $4.35 billion
- Tanker struck by projectile in Strait of Hormuz
Morgan Stanley Downgrades Fusion Pharmaceuticals (FUSN) to Equalweight
March 19, 2024 2:40 PM EDTMorgan Stanley analyst Matthew Harrison downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Overweight to Equalweight with a price target of $21.00 (from $10.00).
The analyst comments "Fusion to be acquired by AstraZeneca for $21/share in cash payable at deal closing (vs. 03/18 closing price of $10.64),... More
Wedbush Downgrades Fusion Pharmaceuticals (FUSN) to Neutral
March 19, 2024 8:52 AM EDTWedbush analyst David Nierengarten downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Outperform to Neutral with a price target of $24.00.
For an analyst ratings summary and ratings history on Fusion Pharmaceuticals click here. For more ratings news on Fusion Pharmaceuticals click here.
Shares of Fusion Pharmaceuticals closed at $10.64 yesterday.
... MoreMidday movers: Nvidia, Coinbase fall; Unilever rises
March 19, 2024 8:08 AM EDT(Updated - March 19, 2024 11:20 AM EDT)
Investing.com -- Main U.S. indexes slipped lower Tuesday, amid caution ahead of the start of an eagerly-awaited Federal Reserve policy-setting meeting.
Here are some of the biggest U.S. stock movers today:
Nvidia (NASDAQ: NVDA) stock fell 2% as the chipmaker gave back some of the impressive gains seen this year after it unveiled its new line of AI chips at its annual developer conference. Shares AMD (NASDAQ:... More
Leerink Partners Downgrades Fusion Pharmaceuticals (FUSN) to Market Perform
March 19, 2024 6:03 AM EDTLeerink Partners analyst Faisal Khurshid downgraded Fusion Pharmaceuticals (NASDAQ: FUSN) from Outperform to Market Perform with a price target of $21.00 (from $17.00).
For an analyst ratings summary and ratings history on Fusion Pharmaceuticals click here. For more ratings news on Fusion Pharmaceuticals click here.
Shares of Fusion Pharmaceuticals closed at $10.64 yesterday.
... MoreFusion Pharmaceuticals (FUSN) Acquired by AstraZeneca (AZN) for $21/sh Cash + $3 CVR
March 19, 2024 4:13 AM EDTFusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radioconjugates (RCs) as precision medicines, today announced the Company has entered into a definitive agreement to be acquired by AstraZeneca (NASDAQ: AZN). The acquisition marks a major step forward in AstraZeneca delivering on its ambition to transform cancer treatment and outcomes for patients by replacing traditional regimens like chemotherapy and radiotherapy with more targeted treatments.
RCs have emerged as a promising modality in cancer treatment over recent years.... More
